NAMS - Latest News
NewAmsterdam Pharma Company N.V. (NAMS), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $3.25B. Beta to the broader market is 0.11.
The article list below shows the most recent NAMS headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent NAMS Headlines
NewAmsterdam Pharma Company N.V. (NAMS) Analyst/Investor Day Transcript
seekingalpha.com - Aug 8, 2026
NewAmsterdam Pharma Company N. V.
NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears
marketbeat.com - Aug 5, 2026
NewAmsterdam Pharma NASDAQ: NAMS used its annual Investor Day to outline its cardiovascular outcomes strategy for obicetrapib, provide updates on addi
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates
zacks.com - Aug 5, 2026
NewAmsterdam Pharma Company N. V.
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
globenewswire.com - Aug 5, 2026
– Announced positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe – – PREVAIL interim analysis planned
NewAmsterdam Pharma to Host Investor Day on August 5, 2026
globenewswire.com - Jul 29, 2026
NAARDEN, The Netherlands and MIAMI, July 29, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N. V.
How News Affects NAMS Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track NAMS's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked NAMS news questions
- What is the latest NAMS news headline?
- The most recent NAMS headline (Aug 8, 2026) is "NewAmsterdam Pharma Company N.V. (NAMS) Analyst/Investor Day Transcript". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the NAMS news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What NAMS news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual NAMS options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.